English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

The European Randomized Study on Screening of Prostate Cancer (ERSPC), based in Rotterdam, has calculated that it would take 1981 patients in the PSA group <3ng/ml to be biopsied to prevent one prostate cancer death.2 Bearing in mind that there is an estimated 1:5000 risk of death from septicaemia after biopsy (regardless of histology), then in 5000 biopsies, this will save 2.7 lives from prostate cancer and kill one patient from the biopsy.

Back to Back: New Zealand should introduce population screening for prostate cancer using PSA testing: No